Mirum Pharmaceuticals IncChange company Symbol lookupSelect an option...MIRM Mirum Pharmaceuticals IncFCELB Fuelcell Energy IncUK Ucommune International LtdCRDF Cardiff Oncology IncTRNR Interactive Strength IncOMGA Omega Therapeutics IncACST Acasti Pharma IncPYPD PolyPid LtdACRX AcelRx Pharmaceuticals IncMI Nft LtdGo
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of therapies for rare and orphan diseases. Its development pipeline consists of two clinical-stage product candidates, Livmarli and volixibat. Its product LIVMARLI (maralixibat) oral solution is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) three months of age and older in the United States and for the treatment of cholestatic pruritus in patients with ALGS two months of age and older in Europe. Its second product candidate, Volixibat is an oral, minimally absorbed agent designed to inhibit ileal bile acid transporter (IBAT), for the treatment of adult patients with cholestatic liver diseases. The Company also offers bile acid product portfolio, which includes Cholbam (cholic acid) and Chenodal (chenodiol).
|
|
|
|
| |
Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.
Options are not suitable for all investors as the special risks inherent to options trading may
expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.
Copyright © 2023. All rights reserved.